J&J MedTech acquires Laminar for $400 million, adds to Biosense Webster
por John R. Fischer, Senior Reporter | December 05, 2023
Business Affairs
Cardiology
Johnson & Johnson has acquired Laminar.
Paying $400 million upfront, Johnson & Johnson MedTech has acquired and made cardiac manufacturer Laminar part of its subsidiary, Biosense Webster, which designs technology for diagnosing and treating cardiac arrhythmia.
Laminar has developed a solution for eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib), which makes them more than five times as likely to experience a stroke. LAA closure is FDA-approved to reduce the risk of thromboembolism in AFib patients who cannot tolerate long-term blood thinners.
Its approach uses rotational motion to eliminate the LAA rather than plugs to occlude it like current commercial catheter-based procedure devices, and the company recently received FDA approval to conduct a U.S. pivotal study, with enrollment to begin in early 2024.
“Laminar’s innovative approach will provide Biosense Webster the opportunity to expand our portfolio in this high-growth market, complement our electrophysiology and intracardiac echo strengths, and deepen our presence with interventional cardiologists and electrophysiologists,” said Jasmina Brooks, president of Biosense Webster, in a statement.
According to Laminar, the left atrial appendage occlusion market is expected to reach $2 billion by 2025.
Because of the deal, Johnson & Johnson has adjusted its expected adjusted earnings per share (EPS) for fiscal year 2023, anticipating an approximate 17 cent drop. It anticipates adjusted EPS ranges to be $9.85 to $9.91 and $9.90 to $9.96, respectively, and for EPS in 2024 to be 15 cents less.
News of the acquisition led JNJ shares to trade modestly lower in premarket November 30, according to Street Insider.
J&J acquired Biosense in 1997 and merged it a year later with its Cordis Webster company to create Biosense Webster. Last year, it acquired cardiac pump maker Abiomed for approximately $16.6 billion, adding more solutions for heart recovery to its Biosense Webster electrophysiology business.
The deal with Laminar includes potential clinical and regulatory milestone payments in 2024 and beyond.
Laminar has developed a solution for eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib), which makes them more than five times as likely to experience a stroke. LAA closure is FDA-approved to reduce the risk of thromboembolism in AFib patients who cannot tolerate long-term blood thinners.
Its approach uses rotational motion to eliminate the LAA rather than plugs to occlude it like current commercial catheter-based procedure devices, and the company recently received FDA approval to conduct a U.S. pivotal study, with enrollment to begin in early 2024.
“Laminar’s innovative approach will provide Biosense Webster the opportunity to expand our portfolio in this high-growth market, complement our electrophysiology and intracardiac echo strengths, and deepen our presence with interventional cardiologists and electrophysiologists,” said Jasmina Brooks, president of Biosense Webster, in a statement.
According to Laminar, the left atrial appendage occlusion market is expected to reach $2 billion by 2025.
Because of the deal, Johnson & Johnson has adjusted its expected adjusted earnings per share (EPS) for fiscal year 2023, anticipating an approximate 17 cent drop. It anticipates adjusted EPS ranges to be $9.85 to $9.91 and $9.90 to $9.96, respectively, and for EPS in 2024 to be 15 cents less.
News of the acquisition led JNJ shares to trade modestly lower in premarket November 30, according to Street Insider.
J&J acquired Biosense in 1997 and merged it a year later with its Cordis Webster company to create Biosense Webster. Last year, it acquired cardiac pump maker Abiomed for approximately $16.6 billion, adding more solutions for heart recovery to its Biosense Webster electrophysiology business.
The deal with Laminar includes potential clinical and regulatory milestone payments in 2024 and beyond.
You Must Be Logged In To Post A CommentRegistoO registro é gratuito e fácil. Aproveite os benefícios dos principais produtos novos e inovadores do mundo. Mercado de equipamentos médicos usados. Registrar agora! |
|
